A quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan and should be rolled out to make MRI scans more accessible to men who need one, according to clinical trial results led by UCL, UCLH and the University of Birmingham.

Lung tumors don’t just evade the immune system. They reshape it at its source. Researchers from the Icahn School of Medicine at Mount Sinai and collaborators report in the September 10 online issue of Nature [10.1038/s41586-025-09493-y] that tumors rewire immune cells in the bone marrow before they even reach the cancer, suggesting a new target to enhance the durability of current immunotherapy. Immunotherapies, which rally the body’s defenses against cancer, have transformed care for many patients. But in solid tumors like non-small cell lung cancer (NSCLC), their success is often blunted by an influx of pro-tumoral macrophages—immune cells that suppress the body’s anti-cancer response. Until now, scientists thought these macrophages turned rogue only after reaching the tumor.

A consortium led by the University of Southampton has received funding to develop next-generation treatments for cancer and chronic inflammation.

A major UK study, led by researchers at the University of Oxford’s Nuffield Department of Primary Care Health Sciences, Oxford University Hospitals NHS Foundation Trust, the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, and Oxford Cancer, has provided the most comprehensive analysis to date of a cancer diagnosis pathway for patients presenting with non-specific symptoms (NSS), such as unexplained weight loss or fatigue. These symptoms can indicate a wide range of conditions, from benign diseases to late-stage cancers, making timely and accurate diagnosis a significant challenge in primary care.

To improve treatment rates for these patients, UCSF researchers designed a CAR T cell therapy and combined it with an older class of diabetes drugs called thiazolidinediones, to enhance NECTIN4 expression and make tumor cells more susceptible to NECTIN4-CAR T therapy.